StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.17−0.00 (-0.57%)

Close on Nov 16, 2026Market cap $18.09MP/E –Yield –

IGC Pharma cash

Cash and short-term investments held at the end of each period.

IGC Pharma's cash was $354.00K at Jun 30, 2026. For fiscal 2026 it was $235.00K, down 42.0% from the year before. Over ten years it grew -16.9% a year on average. The highest annual figure on record is $25.61M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2026Mar 31, 2026$235.00K-42.0%
FY2025Mar 31, 2025$405.00K-66.2%
FY2024Mar 31, 2024$1.20M-64.2%
FY2023Mar 31, 2023$3.35M-68.0%
FY2022Mar 31, 2022$10.46M-28.5%
FY2021Mar 31, 2021$14.63M+101.5%
FY2020Mar 31, 2020$7.26M-71.7%
FY2019Mar 31, 2019$25.61M+1318.1%
FY2018Mar 31, 2018$1.81M-25.3%
FY2017Mar 31, 2017$2.42M+62.2%
FY2016Mar 31, 2016$1.49M+80.8%
FY2015Mar 31, 2015$824.49K-19.7%
FY2014Mar 31, 2014$1.03M-3.6%
FY2013Mar 31, 2013$1.06M+89.1%
FY2012Mar 31, 2012$562.95K–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$354.00K-22.0%
Q4 FY2026CQ1 2026Mar 31, 2026$235.00K-42.0%
Q3 FY2026CQ4 2025Dec 31, 2025$938.00K+99.6%
Q2 FY2026CQ3 2025Sep 30, 2025$1.13M-26.9%
Q1 FY2026CQ2 2025Jun 30, 2025$454.00K-75.1%
Q4 FY2025CQ1 2025Mar 31, 2025$405.00K-66.2%
Q3 FY2025CQ4 2024Dec 31, 2024$470.00K-65.9%
Q2 FY2025CQ3 2024Sep 30, 2024$1.55M-50.5%
Q1 FY2025CQ2 2024Jun 30, 2024$1.82M-6.5%
Q4 FY2024CQ1 2024Mar 31, 2024$1.20M-64.2%
Q3 FY2024CQ4 2023Dec 31, 2023$1.38M-72.6%
Q2 FY2024CQ3 2023Sep 30, 2023$3.12M-54.2%
Q1 FY2024CQ2 2023Jun 30, 2023$1.95M-75.8%
Q4 FY2023CQ1 2023Mar 31, 2023$3.35M-68.0%
Q3 FY2023CQ4 2022Dec 31, 2022$5.03M-57.9%
Q2 FY2023CQ3 2022Sep 30, 2022$6.82M-52.7%
Q1 FY2023CQ2 2022Jun 30, 2022$8.05M-39.5%
Q4 FY2022CQ1 2022Mar 31, 2022$10.46M-28.5%
Q3 FY2022CQ4 2021Dec 31, 2021$11.94M+302.3%
Q2 FY2022CQ3 2021Sep 30, 2021$14.40M+187.9%
Q1 FY2022CQ2 2021Jun 30, 2021$13.32M+70.7%
Q4 FY2021CQ1 2021Mar 31, 2021$14.63M+101.5%
Q3 FY2021CQ4 2020Dec 31, 2020$2.97M-80.5%
Q2 FY2021CQ3 2020Sep 30, 2020$5.00M-73.8%
Q1 FY2021CQ2 2020Jun 30, 2020$7.80M-63.8%
Q4 FY2020CQ1 2020Mar 31, 2020$7.26M-71.7%
Q3 FY2020CQ4 2019Dec 31, 2019$15.19M-44.1%
Q2 FY2020CQ3 2019Sep 30, 2019$19.10M+191.4%
Q1 FY2020CQ2 2019Jun 30, 2019$21.56M+1745.4%
Q4 FY2019CQ1 2019Mar 31, 2019$25.61M+1318.1%
Q3 FY2019CQ4 2018Dec 31, 2018$27.18M+1507.4%
Q2 FY2019CQ3 2018Sep 30, 2018$6.56M+998.2%
Q1 FY2019CQ2 2018Jun 30, 2018$1.17M+238.1%
Q4 FY2018CQ1 2018Mar 31, 2018$1.81M-25.3%
Q3 FY2018CQ4 2017Dec 31, 2017$1.69M+127.3%
Q2 FY2018CQ3 2017Sep 30, 2017$597.00K-36.4%
Q1 FY2018CQ2 2017Jun 30, 2017$345.61K–
Q4 FY2017CQ1 2017Mar 31, 2017$2.42M–
Q3 FY2017CQ4 2016Dec 31, 2016$744.06K–
Q2 FY2017CQ3 2016Sep 30, 2016$939.29K–

More IGC Pharma figures

See a number that looks wrong?